{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT03060551",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "OutcomeAnalysisDispersionValue",
                  "OutcomeAnalysisEstimateComment",
                  "OutcomeAnalysisGroupDescription",
                  "OutcomeAnalysisGroupId",
                  "OutcomeAnalysisNonInferiorityComment",
                  "OutcomeAnalysisNonInferiorityType",
                  "OutcomeAnalysisOtherAnalysisDescription",
                  "OutcomeAnalysisPValue",
                  "OutcomeAnalysisPValueComment",
                  "OutcomeAnalysisParamType",
                  "OutcomeAnalysisParamValue",
                  "OutcomeAnalysisStatisticalComment",
                  "OutcomeAnalysisStatisticalMethod",
                  "OutcomeAnalysisTestedNonInferiority",
                  "OutcomeCategoryTitle",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OutcomeAnalysisDispersionValue": [],
                        "OutcomeAnalysisEstimateComment": [],
                        "OutcomeAnalysisGroupDescription": [],
                        "OutcomeAnalysisGroupId": [
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000"
                        ],
                        "OutcomeAnalysisNonInferiorityComment": [
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed.",
                              "Because most efficacy data consisted of non-parameteric variables, results were shown as median values and interquartile range. The Wilcoxon signed-rank test was performed to analyze differences between baseline and at 2W, 6W, 12W and 24W, respectively, using IBM-SPSS Statistics version 24.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at p < 0.05. Safety profiles were descriptively analyzed."
                        ],
                        "OutcomeAnalysisNonInferiorityType": [
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other",
                              "Other"
                        ],
                        "OutcomeAnalysisOtherAnalysisDescription": [],
                        "OutcomeAnalysisPValue": [
                              "0.256",
                              "0.682",
                              "0.151",
                              "0.516",
                              ">0.999",
                              "0.034",
                              "0.656",
                              "0.096",
                              "0.019",
                              "0.050",
                              "0.372",
                              "0.024",
                              "0.188",
                              "0.372",
                              "0.633",
                              "0.380"
                        ],
                        "OutcomeAnalysisPValueComment": [
                              "p value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)",
                              "p-value (24 weeks-baseline)"
                        ],
                        "OutcomeAnalysisParamType": [],
                        "OutcomeAnalysisParamValue": [],
                        "OutcomeAnalysisStatisticalComment": [],
                        "OutcomeAnalysisStatisticalMethod": [
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)",
                              "Wilcoxon (Mann-Whitney)"
                        ],
                        "OutcomeAnalysisTestedNonInferiority": [],
                        "OutcomeCategoryTitle": [],
                        "NCTId": [
                              "NCT03060551"
                        ]
                  }
            ]
      }
}